Systems that evolve over time and follow mathematical laws as they do so, are called dynamical systems. Lymphocyte recovery and clinical outcomes in 41 allograft recipients conditioned using anti--thymocyte globulin (ATG) and 4.5 Gray total--body--irradiation were studied to determine if immune reconstitution could be described as a dynamical system. Survival, relapse, and graft vs. host disease (GVHD) were not significantly different in two cohorts of patients receiving different doses of ATG.
Introduction.
Allogeneic stem cell transplantation (SCT) results in widely disparate outcomes in individual transplant recipients, regardless of uniformity of histocompatibility criteria applied in donor selection [1, 2, 3] and therapeutic interventions [4, 5, 6 ] utilized for pre transplant conditioning regimens and graft versus host disease (GVHD) prophylaxis. Standard methodology is to examine clinical outcomes using statistical analytic techniques based on probability theory [7, 8] . These analytic techniques are useful in determining odds of clinical outcomes in populations of patients transplanted using uniform conditioning regimens, but are inadequate for determining the course an individual might take following SCT. This is because of the underlying assumption that, within the constraints of certain critical parameters, such as donor type or HLA matching, the probability distribution of these clinical outcomes is essentially random. For example, in patients allografted for myelodysplastic syndrome, the addition of antithymocyte globulin (ATG) to the conditioning regimen reduced the likelihood of developing severe acute GVHD [9] . Similarly, higher levels of donor T cell chimerism at day--30 following reduced--intensity (busulfan+fludarabine) conditioning resulted in a lower probability of relapse following SCT [10] . Such population--based estimates may then be used to guide clinical decision--making at various time points during the transplant process, but individual patients undergoing SCT remain at risk for competing causes of adverse outcomes.
To improve outcome predictions in individuals undergoing SCT in real--time, a closer examination of the biology of transplantation is necessary, specifically, the immunobiology of transplantation. In patients transplanted for management of hematological malignancy treatment failure is often attributable to either the development of life--threatening GVHD or the lack of graft versus malignancy (GVM) effects [11, 12] . These are, in turn influenced by the immune reconstitution following transplantation [13, 14, 15, 16] . Hypothetically, repertoire complexity emerging in the reconstituting cell populations may be driven, in part, by the disparity in minor histocompatibility antigens encountered in each instance of SCT [17, 18] . It has been demonstrated that HLA--matched donor--recipient pairs have extensive variation in their exomes, [19] and in silico this translates to a massive array of minor histocompatibility antigens, which may be presented by the HLA in the recipients [20] . This minor histocompatibility antigen difference may be considered an alloreactivity potential between donors and recipients, and appears to be very large when the number of variant peptide--HLA complexes is accounted for in each pair. Further, the binding affinity distribution of these peptides to the HLA appears to mirror the complex T cell clonal frequency observed in the T cell repertoire in SCT donors and in recipients [21] . These findings, suggest that clinical outcomes related to T cell alloreactivity following SCT may not primarily be stochastic in nature, rather when taking a quantitative perspective may be better considered mathematically to account for the large alloreactivity potential between SCT donors and recipients. Systems that follow mathematically defined laws are common in the natural world and are called dynamical systems [22, 23, 24, 25] . A dynamical system is defined as any iterating physical system, which evolves over time in a manner such that future states of the system are predicated on all the preceding states, and the evolution of the system can be modeled using ordinary differential equations. Such systems will behave either in linear (such as a mass accelerating in proportion to the force applied) or non--linear fashion (such as population growth constrained by environmental pressures). In the context of SCT this implies that if considered as a system of interacting donor T cell clones and recipient antigens, immune reconstitution following SCT is a dynamic, evolving process, which can be modeled mathematically and allow more precise determination of the odds of clinical outcomes such as engraftment, GVHD and survival in an individual [26] . A feature of dynamical systems is that early events in the system set the trajectory of the series of events to follow, and thus determine the eventual outcome. In certain non--linear dynamical systems, this implies that small variations in the early state of the system can produce large measurable effects late in the evolution of this system. In SCT a large body of literature now supports the notion that both early interventions [27, 28, 29] , as well as the magnitude of immune reconstitution early in the course of SCT impacts late clinical outcomes [13, 30, 31] , supporting the validity of considering SCT as a nonlinear dynamical system.
In this paper the results of a prospective randomized phase--2 clinical trial are reported, and considered in the light of immune reconstitution kinetics modeled as a dynamical system. The trial investigated two doses of rabbit anti--thymocyte globulin (ATG; Thymoglobulin, Sanofi--Aventis), in patients undergoing reduced intensity conditioning (RIC). The trial was designed to determine the optimal dosing of ATG to be given in combination with reduced intensity total body irradiation (TBI) to ensure adequate engraftment. The optimal ATG dose should allow adequate immune reconstitution conferring protection from relapse with a lower risk of GVHD, and that regimen would eventually serve as a comparator for conventional RIC regimens in phase III trials. The clinical outcomes from this trial are analyzed with an underlying assumption, that each transplant represents an example of a dynamical system. Each donor--recipient--pair is comprised of a unique set of recipient alloantigens and a set of donor derived immune effectors, interacting over time following the transplant event, in this instance modulated by two different ATG doses. The focus of the work presented here has been on total lymphoid and T cell reconstitution and the resulting clinical effect. We demonstrate that lymphoid reconstitution following transplantation follows the ubiquitous quantitative rules describing constrained growth, i.e., it occurs as a logistic function of time.
Methods.

Patients
Between 2009 and 2013, 41 patients were enrolled on a prospective randomized phase II clinical trial, approved by the institutional review board at Virginia Commonwealth University (ClinicalTrials.gov Identifier: NCT00709592). To be eligible, patients had to be ≤70 years of age, with recurrent or high--risk hematological malignancy. Patients younger than 50 years had to be ineligible for conventional myeloablative conditioning because of comorbidity. The patients were required to have a 7/8 or 8/8 locus matched related (MRD) or unrelated donor (URD), with high--resolution typing performed for HLA--A, B, C and DRB1. Two different doses of ATG were tested in the two arms of this trial, and patients were stratified for donor type (MRD or URD) and disease status (CR1 or >CR1) at the time of randomization. Patient characteristics are given in Table 1 . Patient follow up is updated as of October
2014.
Rabbit ATG & Low--dose Total Body Irradiation Conditioning Regimen
Patients were randomized between two different doses of rabbit--anti--thymocyte globulin, either ATG 2.5 or 1.7 mg/kg, adjusted ideal body weight per day given intravenously from day -9 to -7 (ATG 7.5 or ATG 5.1 cohorts), followed by total body irradiation (TBI) to a total dose of 4.5 Gray, delivered in three 1.5 Gray fractions, administered twice on day -1, with the final dose on day 0 (Supplementary Figure 1) . Uniform supportive care, ATG premedication and antimicrobial prophylaxis were administered (Supplementary material). GVHD prophylaxis was with tacrolimus given orally from day -2 with taper commencing around 12 weeks post transplant, in an initial cohort of patients (n=24), and according to donor derived T cell counts in the remaining patients. Mycophenolate mofetil was given orally at a dose of 15 mg/kg twice daily from day 0 to 30. G--CSF was given at a dose of 5 µg/kg/d from day 4 until myeloid engraftment. Blood stem cells were collected using G--CSF 10 µg/kg/d given subcutaneously on day 1 through 5. Escalating dose DLI was permitted beyond 8 weeks post SCT for the management of declining or persistent mixed chimerism and for disease progression.
Lymphoid reconstitution following SCT
Absolute lymphocyte counts (μL --1 ) (ALC) measured at multiple time points as a part of routine clinical care of the patients following SCT were plotted over time and analyzed using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA). These data were examined for trends over time and further analyzed as a logistic function of time utilizing the equation of the general form,
, (adopted from Prism v 6.00). In this equation, N 0 represents the lymphocyte count at the beginning K is the lymphocyte count at steady state; Nt, is the lymphocyte count at time t following transplant; a, is the time at which growth rate is maximal and an inflection point is observed in the logistic curve, and R is the growth rate of the population. In order to elucidate the initial growth followed by exponential expansion of the lymphocytes, and to eliminate the effect of extraneous therapy on lymphocyte counts (e.g., corticosteroids for GVHD, chemotherapy for relapse, CMV reactivation and therapy) these parameters were determined only for the time post transplant before these clinical events had transpired. ALC following DLI were not considered as a part of this analysis.
T cell engraftment analysis
Donor engraftment was measured using chimerism analyses performed at approximately 4, 8, 12, and 24 weeks following transplant on immunomagnetically separated granulocytes, and total T cells as previously described [13] . Donor--derived CD3+ T cell count (ddCD3) was calculated by multiplying the T cell chimerism (% recipient DNA, expressed as a fraction) with the absolute blood CD3+ T cell count obtained simultaneously. The resulting absolute recipient--derived CD3+ T cell count was then subtracted from the total absolute CD3+ cell count, to obtain a donor--derived CD3+ T cell count. When available, the calculated ddCD3 values for the first three to six months were plotted over time for each patient as a polynomial (cubic) function of time, (y = ax 3 +bx 2 +cx+d) using Microsoft Excel software.
This was done with the assumption that the ddCD3 on day 0 of SCT will be zero. From the resulting polynomial equations for each patient, the differential equation describing the rate of change of ddCD3 at any time point along the curve for each patient was determined (dy/dx = 3ax 2 +2bx+c). The derivative, i.e. rate of change of ddCD3 at day 30 and day 45 was then calculated for each individual using Wolfram/Alpha Online Derivative Solver. These early points were chosen as they represented the earliest clinically important measured ddCD3 value available and because these allowed determination of the T cell expansion rate in the time period immediately following the cessation of MMF. The derivative calculations were also confirmed by manual calculations.
Study Design and Statistical analysis
For this analysis overall survival was taken from the day following transplant to the day of death. GVHD was classified according to consensus criteria. Acute GVHD was graded according to the Glucksberg criteria. GVHD observations were censored if this complication developed after DLI. Disease specific criteria were used for diagnosing relapse or progression. Survival and event--free survival curves (relapse--fatality) for the 5.1--and 7.5--level dose groups are plotted with Kaplan--Meier curves and are compared using the log--rank test. The incidence curves for relapse, acute GVHD, chronic GVHD, DLI use (accounting for the competing risk of mortality) are plotted and compared between dose levels using Grey's test. Wilcoxon rank sum tests are used to compare median percentage chimerism and ddCD3 cell count between dose groups at different times following SCT; this non--parametric test is used because these measures exhibit highly non--symmetric distributions. The R statistical software (version 2.15) was used for all time--to--event analyses, with the survival package used for survival curves, and the cmprsk package used for all competing risk curves.
The rate of change in ddCD3 cell count at day 30 (dx/dy (30)) and day 45 (dx/dy (45) 
Results.
Clinical outcomes with ATG+TBI conditioning
This study was designed to examine the relative impact of two ATG doses in a RIC regimen on immune reconstitution and subsequent clinical outcomes, with the aim of improving survival by limiting fatal GVHD while retaining GVM effects. To date, there is no significant difference in the survival between the two study arms (Log--Rank P = 0.53) ( Figure 1A ). Accounting for the competing risk of mortality, acute GVHD rate in the ATG 5.1 cohort is 27.2% (SE = 0.96%), and in the 7.5 dose group it was 4.5% (SE = 0.21%) (P=0.039). Seven patients developed grade II--IV acute GVHD (6 grade III--IV); six were in the ATG 5.1 arm; one of those patients did not receive tacrolimus after day 10 due to neurotoxicity and was switched to sirolimus. All but one patient developed acute GVHD after immunosuppression was withdrawn, with the median time to maximum grade of acute GVHD being day 130 post--SCT. Similarly, accounting for the competing hazard of mortality, the 1--and 2--year chronic GVHD rates in the ATG 5.1 cohort are both 23.8% (SE = 0.94%), and in the ATG 7.5 group are 31.8% (SE = 1.05%) and 36.8% (SE = 1.16%), respectively (P=0.37) ( Figure 1D ).
Chronic GVHD was diagnosed at a median 172 days post--SCT in 12 patients (4 in the ATG 5.1 arm) and was moderate to severe in 8 patients.
The need for post--transplant cellular therapy intervention, DLI (administered for either mixed chimerism or persistent disease or relapse) was greater in the ATG 7.5 arm. Accounting for the competing risk of mortality, the 1--and 2--year DLI rates in the ATG 5.1 arm are both 8.9% (SE = 0.38%), while in the ATG 7.5 arm it was 40.9% (SE = 1.12%) and 45.5% (SE = 1.21%), respectively (Grey's test P=0.072) ( Figure 1E ). Median time to DLI was 237 days and a median 3 infusions were administered, with a CD3 cell dose ranging from 10 6 to 5x10 7 CD3+ cells/kg. Nine of the thirteen patients receiving DLI developed GVHD following DLI, this was fatal in two cases.
Engraftment
To determine the dose effect of ATG on T cell and myeloid engraftment in this RIC regimen, T cell chimerism and absolute T cell count recovery, as well as granulocyte chimerism were compared between the two arms. T cell chimerism was mixed donor--recipient in a number of patients, with a larger recipient derived component in the ATG 7.5 cohort compared with the ATG 5.1 cohort except at 9 months (where both medians are 0). These differences are significant at 12 weeks (p--value = 0.02), and approach significance at 6, 9 and 12 months (Table 2) . Correspondingly, the ddCD3 cell counts, are higher in the ATG 5.1 cohort than in the ATG 7.5 cohort at every time point (Supplementary figure 2), being significant at 12 weeks (p--value = 0.03), and approaching significance at 4 and 8 weeks and at 9 months post--SCT (Table 2) . Myeloid engraftment was completely donor--derived in all but 3 patients in the ATG 7.5 cohort. Two other patients with MDS had persistent disease with mixed myeloid chimerism, which resolved with withdrawal of immunosuppression in one and with administration of DLI in the other. These results demonstrate that hematopoietic engraftment is superior in the ATG 5.1 cohort.
Lymphoid reconstitution kinetics
In order to study the influence of the rate of immune reconstitution on clinical outcomes in individual 
Determinants of Logistic Patterning
To identify factors influencing logistic growth patterns observed in lymphocyte recovery; ATG dose, donor type and age, CD3+ and CD34+ cell doses infused, tacrolimus level area under the curve for days 15, 30 and 60 were reviewed and did not demonstrate a significant association with the ALC curve logistic patterns recorded. Reasoning that the lymphocyte growth exponent, R, for T cells will be influenced by antigen presentation prior to the period of exponential growth, the monocyte recovery curves following SCT were plotted for each individual and overlaid with the T cell expansion curve.
Monocyte count was used as a surrogate for antigen presenting cells, since dendritic cells would partly arise from this population. Following engraftment, there was correspondence in the lymphocyte and monocyte growth curves, both demonstrating logistic dynamics ( Figure 3A, Supplementary Figure 4) . 
Donor derived T cell recovery kinetics
To identify the cell subset associated with lymphoid expansion and to determine the effect of donor derived T cell recovery kinetics on clinical outcomes, the ddCD3 counts were plotted as a function of time for the first six months after SCT for the patients for whom data was available. (Table 4) . This measure at day 30 is significantly different between patients experiencing GVHD (p--value = 0.0026) and those requiring DLI (p--value = 0.0476), indicating the influence of early donor T cell expansion on alloreactivity.
Discussion.
Patients undergoing HLA matched allogeneic SCT are at risk for competing hazards of relapse, non--relapse mortality and alloreactivity i.e. GVHD or graft rejection, potentially leading to treatment failure [32] . Beyond tumor biology, the two most critical factors influencing treatment failure are: i) regimen related toxicity of the SCT; and ii) T cell reconstitution following transplantation with its effects on alloreactivity and opportunistic infections. Once regimen related toxicity is diminished using RIC regimens, the ability to forecast, and manage the restoration of T cell immunity would be of great value in terms of optimizing clinical outcomes. In this paper we find that T cell reconstitution following SCT is a dynamic process, which can be modeled by equations commonly used to describe growth in biological systems. Further the dynamics of T cell reconstitution have a major impact on important clinical outcomes such as GVHD and engraftment as well as survival. This suggests that the likelihood of certain clinical outcomes may be computed in real time during the course of stem cell transplantation and appropriate therapeutic adjustments made dynamically, rather than at specific time points post transplant.
Systems following logistic dynamics, modeling constrained growth, depicted by the sigmoid curve, are common in biology [22, 23] , describing phenomenon as diverse as population growth (in both the microbial and in the animal kingdom) and enzyme reaction kinetics with saturation. The hypothesis that they should also describe lymphocyte reconstitution following an immuno--ablative SCT is rational and supported by our data. Further support for this concept comes from the observation that as expected, clinical events such as GVHD and infections, and relapse lead to a departure from steady state behavior evident in these curves. An important consideration in reviewing the ALC data presented here is that many different immune cell subsets constitute these curves, NK cells, T cell subsets, and B cells, with all the cell subsets following different growth kinetics, so the ALC growth curves seen here are an average of all those influences. Correlation of these growth curves with donor derived T cell counts however makes it evident that this constitutes the dominant immune cell population leading to the late exponential growth (in the second month following SCT with this regimen) and its subsequent influence on long term clinical outcome, whether it be GVHD after withdrawal of immunosuppression or long term disease control. Once again supporting this idea is the observation of eventual relapse, and DLI need in patients who did not experience this late lymphoid/ddCD3+ cell expansion. The variation in R and N 0 parameters will likely depend on antigen presentation, the state of immunosuppression and the inflammatory milieu at the time of transplant. When considering these parameters as variables in the logistic growth equations, the direct implication is that the clones which are poised to expand at the threshold of the exponential expansion (e.g., at the time of stopping MMF in this regimen), grow rapidly and determine whether a patient gets GVHD or not. In this scenario, if there are many proliferating alloreactive T cell clones, GVHD ensues, but if tolerance was engendered in the very first few days after transplant, GVHD will be less likely to develop. In other words, the conditions in the earliest days after transplantation determine long--term outcomes if the system' is left at steady state. Recently a similar observation has been made in murine transplant models where T cell reactivity to 3 rd party antigens is maintained, even while host--specific alloreactivity is eliminated by administering cyclophosphamide (Cy) on day 3 and 4 post allografting [33] . The Cy works by eliminating the rapidly proliferating alloreactive T cell clones, whilst sparing the non--cycling 3 rd party reactive
clones. An important consideration in the dynamical immune system theory is that if the system is perturbed, for instance by either; i) withdrawal of stable immunosuppression (R changes); or ii) the administration of DLI (new clones introduced, or N 0 changes); or iii) administration of vaccines with cross--reactivity to allo--antigens: GVHD may ensue. Another important property of the dynamical system described here is that, at very low growth rate populations (T cell clones in this case) decline to extinction, while at very high growth rates chaotic behavior with very high variability in magnitude of the populations over time may be observed. Such chaotic behavior may explain the apparent randomness in incidence of alloreactivity over time, specifically GVHD occurrence in HLA matched and mismatched SCT. The observation of fractal organization of the T cell repertoire in normal donors and following SCT supports the notion of chaotic dynamics at work in this model [26] .
The quantitative immune reconstitution model described here is well known, with the familiar sigmoid growth kinetics of lymphocytes and by extension T cell subsets and NK cells, and the salutary effect of early lymphoid recovery on clinical outcomes after SCT [15, 34] . The novelty of this work is in that it formalizes the understanding of the nature of immune recovery post transplant as a dynamical system by clearly demonstrating an exponential expansion of lymphocytes, which occurs at variable rates. In part this observation was made possible by the use of ATG as a component of this conditioning regimen, which by controlling alloreactive T cell expansion in the earliest days following SCT may allow a clearer picture of lymphoid reconstitution to emerge in some patients. Considering the large alloreactivity potential that exists between donors and recipients [19, 20] , T cell--replete allografts may result in a massive proliferation of donor T cells not tolerant of recipient minor histocompatibility antigens. In these patients the oligoclonal T cell proliferation will be observed after allografting and there will be high likelihood of GVHD [35] . According to the logistic growth model, it will be the antigen exposure in the very first days following transplant, which will set the reconstituting T cell repertoire on this GVHD prone trajectory. On the other hand in grafts where this initial proliferation is controlled, either by pre--transplant ATG, or post--transplant Cytoxan or bortezomib; non--alloreactive T cell clones will dominate in the early days of transplant and will expand, out--competing alloreactive clones, and setting the system on a tolerant trajectory [26] .
This dynamical system modeling differs from stochastic modeling of transplant outcomes in individuals, because it allows associations between immune reconstitution kinetics and clinical endpoints (either freedom from GVHD or not). In practice this would imply that immune cell subsets are measured frequently in the first few weeks after transplantation in each SCT recipient. Rate of lymphoid reconstitution at different times following SCT may then allow an estimation of the likelihood of alloreactivity developing in that specific patient, and the corresponding clinical outcome. The probability of the desired outcome, P at time t+1, is dependent on all the states of the system leading up to the time t, preceding t+1; as explained above, the trajectory of the system. This way clinical outcomes may be projected based on the lymphocyte recovery kinetics observed in the first few weeks following SCT. On the other hand in a stochastic model the probability P of the desired outcome at time t+1 is a function of the probability distribution of the health state being observed at time t and is unaffected by states of the system leading up to that time [36] . Therefore an important advantage of dynamical system modeling is that by active measurement and intervention, this allows therapies to be modified on an ongoing basis to achieve desired clinical outcomes. On the other hand, conventional stochastic modeling allows selection of the optimal therapeutic program, but once the treatment is initiated, can only predict the outcomes observed based on prior probability distributions, allowing only empiric therapeutic modifications. Thus dynamical system modeling of immune reconstitution would allow true personalization of patient management. Eventually integrating this with tumor growth kinetics should allow further improvements in clinical management of patients.
In conclusion, we demonstrate that immune reconstitution following SCT may be modeled mathematically using equations that are commonly used to describe population growth. Modeling immune reconstitution following other conditioning and GVHD prophylaxis regimens will allow determination of the degree to which such measurement may be generalizable and as such allow real time adjustments to be made in post--transplant immunosuppression resulting in optimal immunosuppression. Importantly, dynamical system modeling of transplant makes it possible to limit the effect of randomness in predicting clinical outcomes such as GVHD and engraftment and further refine trial design by accounting for immune reconstitution kinetics. 
Supportive care and GVHD prophylaxis
All patients received oral levofloxacin 500 mg daily from day --9 to neutrophil engraftment, valacyclovir 1000 mg three times daily, voriconazole 200 twice daily and sulfamethoxazole--trimethoprm DS twice daily on two days each week from day --9 till taken off tacrolimus following which voriconazole was discontinued and valacyclovir dose was reduced to twice daily. Methylprednisolone 1 mg/kg twice daily was administered on the days of ATG infusion, along with diphenhydramine and acetaminophen.
Tacrolimus levels were maintained at 10--14 ng/mL in the first month following transplant, following which the levels were generally maintained in the 8--12 ng/mL range until day 90 to 120, following which dose was tapered.
The area under the plasma concentration time curve (AUC) for tacrolimus was calculated using the linear trapezoidal method for approximating numerical integrals. All documented serum tacrolimus trough levels (i.e.
collected within 1 hour of the next scheduled dose) from day 0 through day +90 were collected and included in the estimation of the AUC. The trapezoidal AUC was calculated using the equation
where Cp 1 and Cp 2 represent tacrolimus concentrations at times t 1 and t 2 , respectively. The sum total AUC was then calculated for each patient at the following time points: day +15, +30, and +60.
